研究者詳細 - 髙橋　直人

We herein report a case of cutaneous squamous cell carcinoma (SCC) characterized by paraneoplastic hypercalcemia-leukocytosis syndrome. The patient presented with systemic symptoms, including anorexia, a fever, and a tumoral lesion on the upper arm. Laboratory test results revealed hypercalcemia and leukocytosis. A tissue biopsy confirmed SCC, and further investigation revealed elevated parathyroid hormone-related protein (PTHrP) and granulocyte-colony stimulating factor (G-CSF) levels. Immunostaining demonstrated G-CSF production by the tumor cells. Radiation therapy was administered, which improved leukocytosis and decreased G-CSF and PTHrP levels. Through a case report and literature review, we explored the clinical characteristics of tumors that produce G-CSF and PTHrP.

DOI PubMed CiNii Research

Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST

Takahashi N.

International Journal of Hematology ( International Journal of Hematology ) 2025年

DOI

Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression

Kuroki W.

British Journal of Haematology ( British Journal of Haematology ) 2025年

DOI

Successful Salvage Therapy with Pomalidomide, Cyclophosphamide, and Dexamethasone for IgM Myeloma with t(11;14) and Dim CD38 Expression Refractory to Daratumumab, Lenalidomide, and Dexamethasone

Fujishima Takashi, Kobayashi Takahiro, Kobayashi Isuzu, Kitadate Akihiro, Kameoka Yoshihiro, Takahashi Naoto

Internal Medicine ( 一般社団法人日本内科学会 ) advpub ( 0 ) 2025年

We herein present the case of a 73-year-old man with IgM multiple myeloma (IgM-MM) and t(11;14). The tumor cells showed a small lymphoplasmacytic morphology and dim expression of CD38 and CD138. The MYD 88L265P mutation was found to be negative. After plasma exchange, bortezomib and dexamethasone treatments were refractory. Subsequent daratumumab, lenalidomide, and dexamethasone therapy failed to respond despite the standard therapy for non-IgM MM. Subsequently, pomalidomide, cyclophosphamide, and dexamethasone therapies demonstrated a good response, and a stringent complete response was therefore achieved. This case highlights the need for different treatment strategies for IgM-MM compared with non-IgM-MM because the biological features of IgM-MM and non-IgM-MM are different.

DOI CiNii Research

Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: Induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study

Imamura K.

BMJ Open ( BMJ Open ) 14 ( 10 ) 2024年10月

DOI

膜性腎症を合併し多彩な自己抗体陽性を認めた全身性強皮症

橋本眞子, 阿部史人, 齋藤綾乃, 坂口舞, 金澤達郎, 齋藤雅也, 高橋直人

日本リウマチ学会北海道・東北支部学術集会抄録集 ( (一社)日本リウマチ学会-北海道・東北支部 ) 34回 84 - 84 2024年10月

LINC00887はHDAC3との結合を介して多発性骨髄腫細胞の薬剤耐性を誘導する

長田直希, 松岡紗恵, 池田翔, 高橋直人, 安井寛, 古川雄祐, 菊池次郎, 仲宗根秀樹

日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 1 2024年10月

SETD7はt(11;14)陽性多発性骨髄腫に対する新たな治療標的分子となる